This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (62)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

George A. Porter, MD; William M. Bennett, MD; Sheldon G. Sheps, MD

Arch Intern Med. 1990;150(2):280-283.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Widespread availability of the fungal endecapeptide cyclosporine in 1983 ushered in an era of improved success and broader application of organ transplantation. In 1985, a review¹ of the clinical results with immunosuppression using cyclosporine identified nephrotoxic reactions as the most serious adverse effect of cyclosporine²; a 50% incidence of hypertension was also recognized and thought to be more frequent than with previous immunosuppressive regimens. The cause was unknown, and further investigation was encouraged. Other autoimmune diseases, such as psoriasis, primary biliary cirrhosis, rheumatoid arthritis, and type I diabetes mellitus, have been treated successfully with cyclosporine but with similar complications.³

The purpose of this report is to alert the practicing physician regarding these issues and to provide guidance in treating patients. In addition to incidence, the characteristics of cyclosporine-associated hypertension (CAH) will be reviewed along with data supporting various speculated mechanisms. Drug management of CAH and further directions . . . [Full Text PDF of this Article]

Author Affiliations
on behalf of the National High Blood Pressure Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health

From the Division of Nephrology and Hypertension, Department of Medicine, Oregon Health Sciences University, Portland (Drs Porter and Bennett); and the Divisions of Hypertension and Cardiovascular Disease, Mayo Clinic, Mayo Medical School, Rochester, Minn.

Footnotes
Accepted for publication August 22,1989.

Reprint requests to National High Blood Pressure Education Program, Office of Prevention, Education, and Control, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 (Edward J. Roccella, PhD).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?